Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors
Journal of Medicinal Chemistry · 25.05.2023 · 66 (10) · 6811-6835
DOI: 10.1021/acs.jmedchem.3c00205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.05.2023. Verfasst von Tongfei Jing und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, P. R. Ch…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Guangdong Province Introduction of Innovative R&D Team, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
A series of novel compounds bearing a cyclopropyl linkage were designed, synthesized, and evaluated as programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. An optimized compound (1S,2S)-A25 showed potent inhibitory activity against the PD-1/PD-L1 interaction (IC50 = 0.029 μM) with a selected binding affinity with PD-L1 (KD = 1.554 × 10-1 μM). Additionally, under the co-culture with H460/Jurkat cells, (1S,2S)-A25 can reduce the survival of H460 cells in a concentration-dependent way. A liver microsomal assay revealed that (1S,2S)-A25 had favorable metabolic stability. Furthermore, (1S,2S)-A25 displayed favorable pharmacokinetic properties (oral bioavailability of 21.58%) and potent antitumor potency in a LLC1 lung carcinoma model without observable side effects. Data from the flow cytometry and enzyme-linked immunosorbent assays demonstrated that (1S,2S)-A25 suppressed the tumor growth by activating the immune microenvironment. Our study suggests that (1S,2S)-A25 is a promising lead compound for the further development of PD-1/PD-L1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, P. R. China.
- Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island 02881, United States.
ORCID-Profile: Zhenghui Kang, Hang Ma, Xiaolei Zhang, Wenhao Hu
Förderung
- Guangdong Province Introduction of Innovative R&D Team
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Joint Foundation of Guangdong and Macau for Science and Technology Innovation
- Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, Sun Yat-sen University
Zitieren
APA
Jing, T., Zhang, Z., Kang, Z., Mo, J., Yue, X., Lin, Z., Fu, X., Liu, C., Ma, H., Zhang, X., & Hu, W. (2023). Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors. Journal of Medicinal Chemistry, 66(10), 6811-6835. https://doi.org/10.1021/acs.jmedchem.3c00205
Vancouver
Jing T, Zhang Z, Kang Z, Mo J, Yue X, Lin Z, et al. Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors. Journal of Medicinal Chemistry. 2023;66(10):6811-6835. doi:10.1021/acs.jmedchem.3c00205
BibTeX
@article{Jing2023,
author = {Jing, Tongfei and Zhang, Zhijing and Kang, Zhenghui and Mo, Jianshan and Yue, Xiaotong and Lin, Ziyou and Fu, Xiang and Liu, Chang and Ma, Hang and Zhang, Xiaolei and Hu, Wenhao},
title = {Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {10},
pages = {6811--6835},
doi = {10.1021/acs.jmedchem.3c00205}
}
EUVIMED